Market research
ACST Acasti Pharma Inc
NASDAQ USD Healthcare
Latest close
As of 29 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 34M
- P/E ratio
- Not available
- Analyst target
- 7.97
- Dividend yield
- Not available
- Beta
- 1.52
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA00430K8730
- Market cap
- 34M
- P/E ratio
- Not available
- Analyst target
- 7.97
- Dividend yield
- Not available
- Beta
- 1.52
About
About Acasti Pharma Inc
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Research context
Acasti Pharma Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ACST discussion.
5 years, 6 months ago
Acasti Pharma Inc is currently in a long term uptrend where the price is trading 14.2% above its 200 day moving average.
From a valuation standpoint, the stock is 50.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 661.5.
Acasti Pharma Inc's total revenue rose by inf% to $81K since the same quarter in the previous year.
Its net income has increased by 73.3% to $-3M since the same quarter in the previous year.
Finally, its free cash flow grew by 55.4% to $-4M since the same quarter in the previous year.
Based on the above factors, Acasti Pharma Inc gets an overall score of 5/5.